KIYOSU, Japan–(BUSINESS WIRE)–Toyoda Gosei Co., Ltd. (TOKYO:7282) has invested* in ThinkCyte K.K., whose technologies are used for a broad spectrum of applications, including the early detection of leukemia and other diseases, with the aim of solving social issues in the healthcare field.
ThinkCyte is a startup developing and commercializing cell analysis and sorting technology platform using AI-based cell image analysis. The company’s technology to analyze individual cells and sort them will enable faster and more accurate diagnoses than conventional methods. Its technology also holds future promise for use in drug discovery.
Toyoda Gosei has been focusing efforts on product development and collaboration with companies in the field of preventive medicine, to help increase life expectancy. Using its technologies in the molding of plastic materials and mold processing, Toyoda Gosei will cultivate business in the healthcare field through its contributions to the commercialization of devices being developed by ThinkCyte.
* Investment made in October 2023, through Toyoda Gosei’s Corporate Venture Capital Dept., an internal organization dedicated to these investments.
Outline of ThinkCyte
Name
ThinkCyte K.K.
Location
7-3-1 Hongo, Bunkyo, Tokyo, Japan
CEO
Waichiro Katsuda
Established
February 2016
Capital
JPY 1.207 billion (as of August 2023)
Contacts
Toyoda Gosei Co., Ltd.
Contact: Public Relations
[email protected]
